This reduced expression of FGF14-AS2 is closely linked to an enlargement in tumor size, an advanced clinical stage, a higher occurrence of lymph node metastasis, and an overall survival rate that is more unfavorable [52]. Here, FGF14 is linked to metastatic malignant neoplasm in the lymph nodes.